Prostate cancer (PCa) represents a common malignancy among
elder males and one of the leading causes of cancer mortality. It may present
with a variety of clinical behavior, including tumors of very low clinical
significance but also highly aggressive tumors with increased risk of relapse
after initial treatment.
Nowadays, many tumors traditionally treated either by radical
prostatectomy or by external beam radiation therapy are considered
of low clinical significance and such patients are placed under active surveillance
protocols with purpose to reduce overtreatment.
As a result, in the “active surveillance” era, there is a
need of establishing strong prognostic markers identifying aggressive tumors as
well as clinical significant tumors even among these initially characterized of
low or intermediate risk.
No comments:
Post a Comment